Halozyme Therapeutics, Inc.
HALO
NASDAQ
12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
---|---|---|---|---|---|
Revenue | 230.04M | 216.03M | 221.04M | 162.14M | 181.50M |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | 230.04M | 216.03M | 221.04M | 162.14M | 181.50M |
Cost of Revenue | 73.63M | 72.14M | 69.80M | 53.15M | 64.69M |
Gross Profit | 156.41M | 143.89M | 151.24M | 108.99M | 116.81M |
SG&A Expenses | 37.61M | 35.27M | 38.95M | 37.36M | 15.85M |
Depreciation & Amortization | 15.26M | 17.84M | 17.84M | 17.84M | 4.55M |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 126.50M | 125.25M | 126.58M | 108.34M | 85.09M |
Operating Income | 103.54M | 90.78M | 94.46M | 53.80M | 96.41M |
Income Before Tax | 101.18M | 101.76M | 93.16M | 52.24M | 70.79M |
Income Tax Expenses | 15.79M | 19.92M | 18.40M | 12.62M | 13.09M |
Earnings from Continuing Operations | 85.39M | 81.84M | 74.75M | 39.62M | 57.70M |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | 85.39M | 81.84M | 74.75M | 39.62M | 57.70M |
EBIT | 103.54M | 90.78M | 94.46M | 53.80M | 96.41M |
EBITDA | 122.93M | 109.96M | 113.69M | 72.86M | 102.22M |
EPS Basic | 0.66 | 0.62 | 0.57 | 0.29 | 0.43 |
Normalized Basic EPS | 0.49 | 0.43 | 0.44 | 0.24 | 0.42 |
EPS Diluted | 0.65 | 0.61 | 0.56 | 0.29 | 0.42 |
Normalized Diluted EPS | 0.48 | 0.42 | 0.44 | 0.23 | 0.41 |
Average Basic Shares Outstanding | 129.05M | 131.97M | 131.73M | 135.03M | 135.28M |
Average Diluted Shares Outstanding | 131.04M | 134.08M | 133.54M | 137.90M | 138.60M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |